---
title: "ERIS Lifesciences Ltd (ERIS) — Share Price, Financials & Analysis"
symbol: "ERIS"
company: "ERIS Lifesciences Ltd"
canonical: "https://tapetide.com/stocks/ERIS"
isin: "INE406M01024"
nse_symbol: "ERIS"
bse_code: "540596"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 18698.27
generated_at: "2026-09-13T18:26:29.310Z"
---

# ERIS Lifesciences Ltd (ERIS)

Canonical page: https://tapetide.com/stocks/ERIS

## Company

- **NSE Symbol:** ERIS
- **BSE Code:** 540596
- **ISIN:** INE406M01024
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2017-06-29
- **CEO:** Mr. Amit Indubhushan Bakshi
- **Employees:** 3354
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** eris.co.in

## About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

## Latest Price

- **Price:** ₹1355.5
- **Change:** -1.1 (-0.08%)
- **Open:** ₹1356.6
- **Day High:** ₹1362
- **Day Low:** ₹1335.1
- **Previous Close:** ₹1356.6
- **Volume:** 24968
- **As Of:** 2026-09-11T09:59:56+00:00

## Key Fundamentals

Observed at 2026-09-11T04:41:46.714432Z.

- **Market Cap:** ₹18698.27 Cr
- **Classification:** Smallcap
- **P/E (reported):** 28.2
- **P/E (TTM):** 28.99
- **EPS (TTM):** ₹46.75
- **EPS (reported):** ₹27.95
- **Book Value:** ₹281.61
- **Price to Book:** 4.81
- **Dividend Yield:** 0.53%
- **ROE:** 16.62%
- **ROCE:** 15.72%
- **Debt to Equity:** 0.6
- **Revenue (yearly):** ₹3137.2 Cr
- **Net Income:** ₹647.5 Cr
- **EBITDA:** ₹1127.9 Cr
- **52-Week High:** ₹1745
- **52-Week Low:** ₹1200
- **RSI (14):** 55.56

## Tapetide Score

- **Score:** 52 / 100
- **Score date:** 2026-09-04
- **Archetype:** Out of Favour
- **What it means:** Financially sound, yet the market is not rewarding it. Cases like this usually need a specific reason the pessimism is misplaced, and patience for that reason to play out.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Falling
- **Percentile:** 56.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 17.69 | 9% |
| growth | 34.13 | 9% |
| momentum | 27.13 | 12% |
| ownership | 59.45 | 24% |
| quality | 66.87 | 22% |
| valuation | 65.13 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 4.81 times its book value
- Tax rate seems low

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -49.48% | 10.7% | 42.23% |
| ebitda margin growth | 8.77% | 1.1% | 4.6% | -3.41% |
| net income growth | -48.66% | 72.8% | 19% | 12% |
| revenue growth | 15.49% | 7.73% | 23% | 21% |
| roce | 10.3% | 23.39% | 37.29% | 14.96% |
| roe | -48.65% | 45.15% | 13.46% | -21.86% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| Expenses | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 |
| Operating Profit | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 |
| OPM % | 36 | 36 | 27 | 35 | 36 | 34 | 36 | 36 | 36 | 35 | 36 | 34 |
| Other Income | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | -17 | 2 | 2 |
| Interest | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 |
| Depreciation | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 |
| Profit before tax | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 |
| Tax % | 3 | 12 | -4 | 22 | 25 | 25 | 21 | 22 | 22 | 25 | -75 | 20 |
| Net Profit | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 |
| EPS in Rs | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 | 10.28 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 856 | 982 | 1074 | 1212 | 1347 | 1685 | 2009 | 2894 | 3129 | 3230 |
| Expenses | 533 | 637 | 702 | 781 | 858 | 1146 | 1332 | 1876 | 2009 | 2092 |
| Operating Profit | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1018 | 1120 | 1138 |
| OPM % | 38 | 35 | 35 | 36 | 36 | 32 | 34 | 35 | 36 | 35 |
| Other Income | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | -9 | -9 |
| Interest | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 193 | 191 |
| Depreciation | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 280 | 281 |
| Profit before tax | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 639 | 657 |
| Tax % | 6 | 8 | 11 | 10 | 8 | 8 | 8 | 23 | -1 | — |
| Net Profit | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 | 666 |
| EPS in Rs | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.1 | 28.82 | 25.84 | 44.72 | 46.75 |
| Dividend Payout % | 0 | 0 | 13 | 21 | 20 | 26 | 0 | 28 | 16 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 553 | 848 | 1137 | 1283 | 1563 | 1895 | 2182 | 2573 | 2841 | 3889 |
| Borrowings | 1 | 377 | 176 | 0 | 7 | 84 | 877 | 2781 | 2478 | 2359 |
| Other Liabilities | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1366 | 1415 | 861 |
| Total Liabilities | 692 | 1408 | 1502 | 1502 | 1785 | 2226 | 3410 | 6734 | 6747 | 7123 |
| Fixed Assets | 232 | 771 | 761 | 875 | 854 | 918 | 2568 | 4319 | 5306 | 5188 |
| CWIP | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 171 |
| Investments | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 62 |
| Other Assets | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2379 | 1307 | 1702 |
| Total Assets | 692 | 1408 | 1502 | 1502 | 1785 | 2226 | 3410 | 6734 | 6747 | 7123 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1065 | 538 |
| Cash from Investing Activity | -184 | -590 | -5 | 123 | -323 | -320 | -975 | -1828 | -78 | -369 |
| Cash from Financing Activity | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1380 | -881 | -314 |
| Net Cash Flow | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 105 | -145 |
| Free Cash Flow | 150 | 210 | 186 | 125 | 350 | 258 | -550 | 357 | 910 | 241 |
| CFO/OP | 94 | 94 | 85 | 87 | 103 | 94 | 68 | 87 | 114 | 59 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 | 79 |
| Inventory Days | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 | 200 |
| Days Payable | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 210 | 170 | 151 |
| Cash Conversion Cycle | 84 | -40 | 28 | -12 | 30 | 44 | 70 | 48 | 59 | 129 |
| Working Capital Days | 23 | -13 | -17 | 59 | 64 | 75 | 50 | -296 | -49 | -71 |
| ROCE % | 60 | 34 | 26 | 25 | 27 | 25 | 17 | 11 | 12 | 14 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 54.91% | 54.9% | 54.9% | 54.88% | 54.87% | 54.86% | 54.85% | 54.83% | 54.85% | 54.85% | 53.92% | 54.14% |
| FIIs | 13.2% | 13.13% | 14.27% | 14.59% | 8.01% | 8.35% | 8.43% | 8.4% | 7.21% | 6.85% | 6.39% | 5.75% |
| DIIs | 14.53% | 13.86% | 15.63% | 16.23% | 18.64% | 18.06% | 18.07% | 18.17% | 19.36% | 20.32% | 20.35% | 20.72% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 15.47% | 15.67% | 14.24% | 13.53% | 10.51% | 9.29% | 9.16% | 9.12% | 9.12% | 8.51% | 10.06% | 10.1% |
| Others | 1.9% | 2.44% | 0.95% | 0.77% | 7.96% | 9.43% | 9.49% | 9.47% | 9.45% | 9.48% | 9.26% | 9.29% |
| No. of Shareholders | 42245 | 46496 | 51753 | 44176 | 46346 | 53314 | 50087 | 52225 | 59438 | 54713 | 51656 | 50798 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 6 / 4 / 9

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1320.73 | Buy |
| EMA (10) | 1332.04 | Buy |
| SMA (20) | 1324.09 | Buy |
| EMA (20) | 1334.73 | Buy |
| SMA (50) | 1376.83 | Sell |
| EMA (50) | 1358.63 | Sell |
| SMA (100) | 1380.66 | Sell |
| EMA (100) | 1379.01 | Sell |
| SMA (200) | 1410.52 | Sell |
| EMA (200) | 1410.61 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 55.15 | Neutral |
| MACD (12,26,9) | -9.12 | Buy |
| Stochastic (14,3,3) | 90.41 | Sell |
| ADX (14) | 23.13 | Neutral |
| Williams %R (14) | -6.71 | Sell |
| ATR (14) | 32.2 | Neutral |
| ROC (12) | 3.42 | Buy |
| Stoch RSI (14) | 98.34 | Sell |
| UO (7,14,28) | 52.93 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 10 | 90.91% |
| Hold | 1 | 9.09% |
| Sell | 0 | 0% |

Based on 11 analyst ratings, observed at 2026-09-11T04:41:44.751069+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - India Ratings affirmed Eris Lifesciences' long-term issuer and bank facilities rating at IND AA/Stable on 8 May 2026. | [Announcement under Regulation 30 (LODR)-Credit Rating 8 May - India Ratings affirmed Eris Lifesciences' long-term issuer and bank facilities rating at IND AA/Stable on 8 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c560d494-b13e-434f-ade4-7bb0e72f3581.pdf) |
| 5h - HALMED inspected Swiss Parenterals Units 1 and 2; procedural observations received, with EU-CDMO commercialization delayed. | [INSPECTION OF SWISS PARENTERALS UNITS 1 AND 2 BY HALMED, CROATIA 5h - HALMED inspected Swiss Parenterals Units 1 and 2; procedural observations received, with EU-CDMO commercialization delayed.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ec77bb35-4db6-43af-9c59-86df48465c1e.pdf) |
| 5 Mar - Eris to attend Investec India Conference in Mumbai on March 10, 2026; management 1x1 and group meetings. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Mar - Eris to attend Investec India Conference in Mumbai on March 10, 2026; management 1x1 and group meetings.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/73a68a09-7f59-485e-995f-04b64d8c6f64.pdf) |
| 31 Mar - Eris Lifesciences completed acquisition of Velbiom Probiotics' probiotics business; transaction closed on March 31, 2026. | [Closure Of The Transaction Related To Acquisition Of Probiotics Business Of Velbiom Probiotics Private Limited. 31 Mar - Eris Lifesciences completed acquisition of Velbiom Probiotics' probiotics business; transaction closed on March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/78fe151f-2b03-4b97-b47b-cc2ce5ab524b.pdf) |
| 28 Feb - BSE and NSE each fined Eris ₹65,000 on Feb 27, 2026 for Regulation 17(1) board composition non-compliance. | [Imposition Of Fine By BSE Limited And National Stock Exchange Of India Limited 28 Feb - BSE and NSE each fined Eris ₹65,000 on Feb 27, 2026 for Regulation 17(1) board composition non-compliance.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/45261d1c-1f08-4e30-b924-f23c7612c38a.pdf) |
| 27 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2026 results for designated persons. | [Closure of Trading Window 27 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2026 results for designated persons.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bf1006f6-0873-4236-b333-6e761d83a86f.pdf) |
| 27 Mar - INR 75 crore corporate guarantee to EBPL for HDFC Bank term loan, dated March 27, 2026. | [Corporate Guarantee 27 Mar - INR 75 crore corporate guarantee to EBPL for HDFC Bank term loan, dated March 27, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0532d2c2-a6b3-403c-b104-a1db4d7f7003.pdf) |
| 24 Feb - Eris partners with Natco to commercialise CDSCO-approved generic semaglutide in India; launch expected March 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 24 Feb - Eris partners with Natco to commercialise CDSCO-approved generic semaglutide in India; launch expected March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ada5a8cc-9e4f-4b91-8109-529e4d9f2f06.pdf) |
| 23 Feb - Eris Lifesciences meeting Ajanta India Fund in Mumbai on 26 Feb 2026 at 10:00 AM (in-person). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Feb - Eris Lifesciences meeting Ajanta India Fund in Mumbai on 26 Feb 2026 at 10:00 AM (in-person).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/64172d41-3ac6-4dd3-8e07-939ffe958f13.pdf) |
| 20 Mar - Launch of generic Semaglutide ‘SUNDAE’ in India on 21 March 2026; pricing from ₹1,290/month; pen in April. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 20 Mar - Launch of generic Semaglutide ‘SUNDAE’ in India on 21 March 2026; pricing from ₹1,290/month; pen in April.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/127bc666-37e4-458e-8894-2a4b6ac521e6.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Rumour Verification - Regulation 30(11)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7bc81c5-380a-421d-88d7-4d0c942b2edc.pdf) |
| 2026-09-09 | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Availing Term Loan From Axis Bank](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04c9e327-8995-42b1-bdc4-cd0a69b0106f.pdf) |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e5248b1-042b-41c5-8ac6-eea93c2a1196.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66ec9406-9df0-4fc6-82cf-0633c7a448e7.pdf) |
| 2026-09-02 | [Annual General Meeting Of The Company Scheduled On September 25 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f61bc01e-1790-4105-a30e-c5c73fba2398.pdf) |
| 2026-09-02 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd6b6273-5f56-493a-85f8-324a5eea3c82.pdf) |
| 2026-09-02 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f163490-9233-4f27-ad42-54ee5f3d4231.pdf) |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e05a5456-f4e0-44c5-9028-ec1fa69a61bf.pdf) |
| 2026-08-31 | [Board Meeting Outcome for Outcome For Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48584a1b-373e-457d-b630-c7685e82c9f2.pdf) |
| 2026-08-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72ac27ab-1ef4-4f04-8382-ecef0d120739.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4759601a-79b1-4863-9ab2-854f5cb3005f.pdf) |
| 2026-05-26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3f948bb-cf90-49a0-b82f-6ffb3ea9844c.pdf) |
| 2026-02-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8016781a-c937-40e2-8b0a-c834b559a52e.pdf) |
| 2025-11-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6530efc-ce16-4817-b2e8-046cb04387ed.pdf) |
| 2025-08-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=35bb43cc-d78b-41bb-ac4d-6a1e8ba46050.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7de2249-be80-45e8-8a35-6dc4bd2e1430.pdf) |
| 2025-02-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=88ddfbb8-52af-4bcb-b79c-b431ef28deb8.pdf) |
| 2024-11-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5feadbf2-b6b7-4ee1-a3f6-accf55dc681e.pdf) |
| 2024-08-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22d5725b-2c22-493f-abab-558e99332d8e.pdf) |
| 2024-05-28 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d494d8d-67f5-43fd-bf7d-13b154d6c6f3.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-29 | [Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9910476a-8aad-4f47-a3af-a6108bb0e590.pdf) |
| 2026-05-20 | [Financial Results For The Quarter And Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2dfb263-e8a7-45f0-a141-72fc73aab3a2.pdf) |
| 2026-02-13 | [Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b3ed5a8c-5633-4cce-a615-1394a3d82dba.pdf) |
| 2025-11-12 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6ae8880-fb55-466f-94b7-135922b84d1c.pdf) |
| 2025-08-05 | [Unaudited Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=febc630f-73fc-419d-8723-6abecc11fe56.pdf) |
| 2025-05-19 | [Financial Results For Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f58f50cb-2cc3-43c2-b67e-0aa42d086848.pdf) |
| 2025-02-04 | [Financial Results For The Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ba4d4c3-a91b-40a4-b70c-73a14494fd11.pdf) |
| 2024-10-25 | [Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d781a167-448e-4557-bf0e-5f61a1714c69.pdf) |
| 2024-08-02 | [Financial Results For The Quarter Ended 30 June 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d52a18a0-4ce6-493a-9d9d-fc5de686eb99.pdf) |
| 2024-05-21 | [Financial Results For Quarter And Year Ended 31St March 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7d60efc-6f94-4f51-b438-94775fdc8320.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4e16e31-9436-4e64-af1c-aee43dc3134d.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b0e36dff-c5fd-4895-8ee8-044acfcea60b.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72b59bc9-f080-4758-a1b5-011cba783b2f.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf3953dd-4192-4e75-bb18-ef12c6218972.pdf) |
| 2025-08-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43898fb3-5cce-4a07-a7c3-23a5d48ec076.pdf) |
| 2025-05-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48d5ff7a-2fcc-4fb8-8145-41787223363b.pdf) |
| 2025-02-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72908deb-fb0d-4e8f-8d34-bc1eea5aecab.pdf) |
| 2024-10-25 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f54a2a0-d0a2-40e3-94a2-4bc3d50329d7.pdf) |
| 2024-08-02 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4122c193-0660-42e7-a5a6-6515c8fea74a.pdf) |
| 2024-05-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38959a43-f6a5-44f8-a6da-60c97a8fb0e1.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/79f1006e-99f9-4766-be63-a36922f8387a.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6579cb00-4865-45c5-bd01-558683663330.pdf) |
| Mar 2023 | [Concall - Mar 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cf1f0e8-b7cf-4f70-aa33-0b2e0b258cbc.pdf) |
| Mar 2023 | [Concall - Mar 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4cf1f0e8-b7cf-4f70-aa33-0b2e0b258cbc.pdf) |
| Jan 2023 | [Concall - Jan 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/eaaac04b-0902-4030-8b88-2477f2762fc5.pdf) |
| Feb 2022 | [Concall - Feb 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/54cda3c5-e5c6-41fe-93ca-ef1db3524fc0.pdf) |
| Aug 2022 | [Concall - Aug 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0a015877-9d65-4cac-9fac-c90fdcba7da8.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/15cd9453-3801-4719-b033-bcec14b26fdd.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/22a2491c-a188-41d3-9b38-cf59ea6d198b.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2081cfd2-6878-4f61-aea3-950b2927c0b8.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/540596/74122540596.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2023-11-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c44fac3-578a-4751-baf7-230ae9bf4a15.pdf) |
| 2023-08-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1888b979-4dfe-470f-8294-dd6969aea380.pdf) |
| 2023-05-17 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f954922-c5f0-4fe9-90ac-99c3cf488144.pdf) |
| 2023-03-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7de0d7d3-646e-46fe-ad01-8dc688bade25.pdf) |
| 2023-01-17 | [AUDIO RECORDING OF THE EARNINGS CONFERENCE CALL ON THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ac7e9c7-35a5-453f-8f88-eb76d98c04c4.pdf) |
| 2022-10-20 | [AUDIO RECORDING OF THE EARNINGS CONFERENCE CALL ON THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99743703-c397-481c-a85d-4f9285348606.pdf) |
| 2022-08-05 | [AUDIO RECORDING OF THE EARNINGS CONFERENCE CALL ON THE CONSOLIDATED AND STANDALONE UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER YEAR ENDED 30 JUNE 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be3951ba-affb-4661-b7eb-d7d15c73a9c7.pdf) |
| 2022-05-05 | [AUDIO RECORDING OF THE EARNINGS CONFERENCE CALL](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9065fdab-b265-4f7f-87a3-cf075413c5d3.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:26:29.310Z.